Medtronic announces MiniMed as name for planned New Diabetes Company
GALWAY, Ireland, June 12, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company's roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world.
"Our journey began in 1983, when visionary entrepreneur Alfred E. Mann founded MiniMed and revolutionized diabetes care with many first-of-its-kind innovations that pushed the boundaries of care and helped simplify life with diabetes for countless people around the world," said Que Dallara, current EVP and President of Medtronic Diabetes and Chief Executive Officer designate of MiniMed. "We're thrilled to honor this rich 40-year legacy with a name that carries deep meaning and trust. As we step forward into this new and exciting chapter, we'll focus relentlessly on fulfilling our Mission to make diabetes more predictable so everyone can embrace life to the fullest."
Managing diabetes can feel draining and exhausting due to the constant mental and physical demands to keep glucose levels in a healthy range. Every meal and activity requires careful calculation — counting carbs, adjusting insulin, and monitoring levels to prevent dangerous low and high blood sugars that can result in both short- and long-term complications. The company's Mission is inspired by the desire to introduce more stability and predictability with technology that helps push diabetes management into the background.
For many employees, the Mission hits close to home—over 70% of those surveyed have a personal connection to diabetes. That includes Key Payton, who has been with the company for over a decade and was diagnosed with type 1 diabetes in 1960. "When I was just three years old, doctors told my parents I likely wouldn't live past 10. But here I am, 65 years later, defying the odds and living my best life. I've experienced firsthand how the company has transformed diabetes care and personally helped me beat those early odds in astounding ways," said Payton. "I'm forever grateful for the hope and support they've given me every day for nearly three decades. Today, I'm a proud user of the MiniMed™ 780G system,** and my Time in Range § has never been better. I'm finally sleeping through the night and worrying less about my diabetes — it's freeing."
Based in Northridge, California, the Diabetes business is a passionate team of more than 8,000 employees dedicated to pushing the boundaries of innovation, developing breakthrough technologies that reduce burden, enhance quality of life, improve health outcomes, and redefine standards of care.
Medtronic is targeting completion of the planned separation within 18 months of the initial announcement, subject to customary conditions and legal requirements including consultations with works councils and other employee representative bodies.
Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to Medtronic's ability to satisfy the necessary conditions to consummate the separation of its Diabetes business on a timely basis or at all, Medtronic's ability to successfully separate its Diabetes business and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders), MiniMed's ability to succeed as a standalone publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of Medtronic. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances. While a split-off is Medtronic's current preferred separation structure, a final decision has not been reached at this time. The separation is expected to occur through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof, of the company's remaining shareholding in MiniMed.
**MiniMed™ 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. For details, see https://bit.ly/780gRisks
§ Refers to SmartGuard™ feature. Individual results may vary.
Ryan Weispfenning
Investor Relations
+1-763-505-4626
SOURCE Medtronic plc
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Style Blueprint
15 hours ago
- Style Blueprint
Meet Deeannah Seymour, Founder of pH-D Feminine Health
Share with your friends! Pinterest LinkedIn Email Flipboard Reddit Deeannah Seymour turned an awkward problem into an entrepreneurial revolution. After discovering boric acid could solve a deeply personal issue, she founded pH-D Feminine Health and launched a quiet uprising in women's wellness. What began with a single product has grown into a movement of education and empowerment. Meet the woman sparking smarter conversations and redefining how we care for our bodies, Deeannah Seymour. Pin What first sparked the idea for pH-D Feminine Health? It's true what they say … necessity is the mother of invention. I had struggled with my own feminine care issues, and I was looking for a holistic solution backed by science. I found it in an ingredient called boric acid, in the form of vaginal suppositories. This ingredient changed my life, and I knew I had to find a way to bring it to market, knowing it would benefit millions of women. Have you found it tricky to start the dialogue about feminine health? Since day one of starting pH-D, we have been intentional about creating a platform where we can have open, honest conversations surrounding feminine health. Our brand was one of the first to openly discuss and educate on two of the top reasons women will visit a doctor: feminine odor and itch. In doing so, we're working to remove the shame and stigma associated with these deeply personal issues that most women experience at some point in their lives. It's been incredible to witness the effects of creating a safe space for these conversations. Women (and men alike) are engaging and tagging each other … all in an effort to lift each other up and help friends or loved ones find solutions for their feminine health issues. We're proud to announce the launch of our boldest initiative yet: Raise Your Vagina iQ™, a nationwide campaign that kicked off with two billboards in Times Square, joined by the always-fabulous Sonja Morgan of The Real Housewives of New York City. This movement was born from a decade of witnessing just how many women struggle to describe what's happening with their own bodies because they were never taught the accurate, anatomical language to do so. Instead, many were encouraged to use vague or 'softer' terms, reinforcing the idea that real words are somehow inappropriate. That language gap has real consequences, especially in medical settings, where too often, women don't receive the care they need simply because they can't clearly express their symptoms. To help bridge that gap, we created a fun, accessible online quiz and educational platform that empowers women (and men!) to better understand and communicate about feminine health. Are you a VagiNewbie, a VaGenius, or maybe even a VaGedictorian? Take the quiz and find out because smarter words lead to smarter care. Pin Women's health has often been misunderstood or ignored. How did you decide where to begin making a difference in such a sensitive space? It's no secret that women's health has historically been underfunded, under-researched, and undervalued — and our story is a powerful example of that. The solution I brought to market, boric acid suppositories, had been used for decades but was only available through expensive, inconvenient compounding pharmacies. Legacy companies overlooked it entirely because there was no intellectual property protection, meaning anyone could replicate the product once it was launched. That didn't stop me. I wasn't motivated by exclusivity; I was driven by purpose. I had experienced firsthand how life-changing this product could be, and I felt a moral obligation to make it accessible to the millions of women who needed it. We didn't expect just how massive the unmet need truly was. By introducing boric acid suppositories into mainstream retail, we didn't just launch a product — we created an entirely new category in the feminine care industry. And that category has given women across the country a safe, effective, affordable alternative they didn't even know was possible. Pin What are some of your most memorable 'pinch-me' moments? Some of my most unforgettable 'pinch-me' moments come from conversations with our customers and the healthcare providers who trust and recommend our products. I've had thousands of deeply moving interactions — many tearful — where women have shared that our products changed their lives, restored their confidence, saved their marriages, or finally gave them relief after years of suffering. Providers have told me we've transformed how they practice medicine and helped them significantly reduce their reliance on antibiotics. There's no greater reward than knowing the work my team and I are doing is truly making a global impact on women's health. Where do you see the conversation around women's wellness heading in the next few years, and what change would you love to see? Over the past two years, we've seen a powerful shift in the conversation around women's health, particularly when it comes to menopause. And it's long overdue. My own mother endured menopause in silence because it simply wasn't talked about. Today, thanks to high-profile women who are openly sharing their experiences, more women feel empowered to speak up, seek care, and finally feel seen. As a result, many are reclaiming their health, energy, and lives. That said, we still have a long way to go, especially when it comes to equitable representation in clinical trials and the development of treatments truly tailored to women. But I believe we're at a tipping point. Women are starting to demand better care for themselves and future generations. And that demand is what will ultimately lead to better outcomes, better innovation, and a dramatically improved quality of life for women everywhere. Pin You spend a lot of time helping others. What do you do to embrace your own self-care? I'm on the road for at least six months of the year. A year ago, with a renewed focus on my health, I joined an all-women's gym called TNB Fitness. When I'm in town, I get up at 5 a.m. so I can be in the gym at 6 a.m. and in the office by 8 a.m. When I'm on the road, I get to the hotel gym or try to move as much as I can. Sometimes, it's a fast-paced walk (or run) through the airport. I also love my pop-up infrared sauna. What's something about you that might surprise people? I am a living organ donor, an experience that forever changed my life. Nearly 11 years ago, I donated a kidney to my friend's four-year-old son, Jake. Saying yes to that decision taught me one of the greatest lessons of my life: how to quiet the noise, listen to where we're being guided, and choose faith over fear. Pin What's the best piece of advice you've ever received? One of the most lasting lessons my dad taught me was simple: 'Whatever is worth doing, is worth doing well.' That quote still sits on my desk today. He reminded us often that no task, no matter how small or routine, was beneath our best effort. Whether it was a major project or a menial chore, doing it well meant doing it with integrity, so it wouldn't have to be redone or regretted. That mindset has stayed with me throughout my life and career. Outside of faith, family, and friends, what three things can't you live without? Bow (our black German Shepherd), Mexican food, and traveling. ********** For more inspiring stories, visit our FACES archives! About the Author Jenna Bratcher Jenna Bratcher is StyleBlueprint Nashville's Associate Editor and Lead Writer. The East Coast native moved to Nashville 17 years ago, by way of Los Angeles. She is a lover of dogs, strong coffee, traveling, and exploring the local restaurant scene bite by bite.
Cision Canada
a day ago
- Cision Canada
STATEMENT - CMA reflects on National Indigenous Peoples Day Français
OTTAWA, ON, June 21, 2025 /CNW/ - On this National Indigenous Peoples Day, the Canadian Medical Association (CMA) reflects on the rich history, strength and resilience of First Nations, Inuit and Métis Peoples. This year marks the 10 th anniversary of the Truth and Reconciliation Commission of Canada's report, which exposed the devastating legacy of Canada's residential schools, and the sixth anniversary of the report from the National Inquiry into Missing and Murdered Indigenous Women and Girls. We acknowledge and honour the stories that survivors have shared to help guide us toward a better future. With great humility, we continue our own reconciliation journey led by an Indigenous Guiding Circle composed of health leaders, Elders and Knowledge Keepers. This journey includes working in partnership to combat anti-Indigenous racism in health care and to support the medical profession in making the system safer for First Nations, Inuit and Métis patients and providers. In updating our Code of Ethics and Professionalism, our goal is to better reflect physicians' shared values in supporting patients and providers from Indigenous communities. Alongside Indigenous partners, we're leveraging our voice to also call on the federal government to reintroduce important First Nations clean water legislation and support First Nations, Inuit and Métis-led health care. Our commitment extends to amplifying Indigenous voices and highlighting critical issues through the Indigenous Health Journalism Fellowship. On National Indigenous Peoples Day, we recognize the importance of acknowledging the truth, rebuilding trust and taking the steps necessary to fulfill our promise of transforming the health system to provide culturally safe, trauma-informed care for Indigenous Peoples. Dr. Margot Burnell President, CMA SOURCE Canadian Medical Association
Cision Canada
a day ago
- Cision Canada
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles. In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic ®) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile. In a Phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles in patients with T2DM after 16 weeks of treatment. Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba ®). BEIJING and BRIDGEWATER, N.J., June 21, 2025 /CNW/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection and once-weekly basal insulin analog GZR4 injection during a poster presentation at the American Diabetes Association (ADA)'s 85th Scientific Sessions. Bofanglutide injection and GZR4 injection are investigational drugs that have not yet been launched in any country. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. Bofanglutide injection: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus (T2DM) In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate glycemic control through diet and exercise and/or irregular use of antidiabetic medications, were randomized to receive either bofanglutide injection (N=27) or placebo (N=9) once weekly (QW) for 23 weeks, with a dose escalating from 1.5 mg to 13 mg. The key efficacy endpoint was HbA1c change from baseline to week 23. After 23 weeks of treatment, the mean HbA1c change from baseline in the bofanglutide groups was -1.81% compared to 0.12% in the placebo group, with an estimated treatment difference of -1.93% points *. The proportion of participants achieving an HbA1c target of <7.0% and ≤6.5% was 57.7% and 46.2%, respectively, compared to zero in the placebo group. In terms of weight management, participants treated with bofanglutide experienced a mean reduction in body weight of 6.92 kg from baseline, corresponding to a 9.3% decrease, compared to a minimal reduction of 1.2% in the placebo group. Furthermore, bofanglutide showed comprehensive improvements over placebo in multiple metabolic parameters, including fasting plasma glucose (FPG), glycated albumin (GA), waist circumference (WC), blood pressure, and lipid profiles. In terms of safety, bofanglutide was well tolerated in patients with T2DM. Consistent with known GLP-1 RAs, the most common adverse events were gastrointestinal-related, primarily observed during the early dose-escalation period with mostly mild to moderate in severity. No hypoglycemic events or investigational product-related serious adverse events were reported during the study. Bofanglutide injection: A Multicenter, Randomized, Open-label, Active comparator-controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of bofanglutide Injection versus Semaglutide (Ozempic ®) in Chinese Patients with T2DM In this Phase 2b clinical trial (NCT06256549), a total of 272 eligible Chinese patients with T2DM, who had inadequate glycemic control either after lifestyle intervention or despite stable use of oral antidiabetic drugs (OADs) for at least 3 months, were randomized to receive bi-weekly (Q2W) 12 mg (N=55), 18 mg (N=54), 24 mg (N=55) bofanglutide injections, or once-weekly (QW) 24 mg (N=54) bofanglutide injections, or 1 mg semaglutide (Ozempic ®, N=54) for 24 weeks of treatment, including the dose-escalation period. The primary endpoint was HbA1c change from baseline to week 24. After 24 weeks of treatment, the mean reductions in HbA1c from baseline were 1.87%, 2.28%, and 1.94% in the bofanglutide groups at 12 mg, 18 mg, and 24 mg Q2W, respectively, and -2.32% in the 24 mg QW group. All these treatment regimens showed greater HbA1c reductions compared to the semaglutide group (-1.60%), with the 18 mg Q2W and 24 mg QW bofanglutide groups demonstrating statistically significant superiority (p<0.001) *. Among drug-naïve patients with inadequate glycemic control despite lifestyle interventions, the 18 mg Q2W bofanglutide group achieved a mean HbA1c reduction of 2.98%, which was significantly greater than that observed with semaglutide (-2.04%; p<0.001)*. The proportions of patients achieving HbA1c target of <7.0% were 63.0% to 73.6% in the Q2W bofanglutide group, 75.0% in the QW bofanglutide group, and 70.0% in the semaglutide group. For the HbA1c ≤6.5% target, the corresponding proportions were 58.2% to 67.9%, 69.2%, and 62.0%, respectively. Furthermore, the mean change in body weight for all bofanglutide groups from baseline to week 24 ranged from -4.26 to -6.54 kg, compared to -3.25 kg in the semaglutide group *. Bofanglutide also greatly improved FPG, blood pressure, lipid profiles, and other metabolic parameters. In this study, bofanglutide was g enerally well tolerated, with safety and tolerability consistent with other known GLP-1 RAs. The most common adverse events were gastrointestinal-related, mostly mild to moderate in severity, and no sever e hypoglycemic events were observed. GZR4 injection: A Multicenter, Randomized, Open-label, Active-controlled, Treat-to-target Phase 2 Clinical Study Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin degludec (IDeg, Tresiba ®) in Chinese patients with T2DM This Phase 2 clinical study (NCT06202079) enrolled a total of 83 Chinese patients with T2DM who had inadequate glycemic control on OADs (Part A), and 96 patients with inadequate control on OADs combined with basal insulin therapy (Part B). Participants were randomized to receive QW GZR4 injection (Part A: N=42; Part B: N=41) or once-daily IDeg (Tresiba ®) injection (Part A: N=48; Part B: N=48) for 16 weeks of treatment. The primary efficacy endpoint was the change in HbA1c from baseline to week 16. After 16 weeks of treatment, in patients from Part A, the mean change in HbA1c was comparable between GZR4 groups and IDeg groups (−1.50% versus -1.48%, p = 0.90). The proportion of participants achieving HbA1c target of <7.0% was 59.5% in the GZR4 group and 70.7% in the IDeg group, while the proportion achieving HbA1c target of ≤6.5% was 38.1% and 29.3%, respectively. In patients from Part B, GZR4 demonstrated significantly greater HbA1c reduction compared to IDeg (-1.26% vs -0.87%; p<0.01), with a higher proportion of patients achieving HbA1c targets of <7.0% and ≤6.5% (52.1% vs 29.2%; 25.0% vs 10.4%). In addition, improvements from baseline in FPG and time in range (TIR) were comparable between the GZR4 group and IDeg group. GZR4 achieved effective glycemic control without the need for a loading dose at the first administration, while the total weekly insulin dosage (mole) for GZR4 was approximately 40–50% of that for IDeg (p<0.001). In terms of safety, the incidence of adverse events was similar between the two groups. No severe hypoglycemic events or investigational product-related serious adverse events were reported during the study. * The clinical data were presented as mean (SE) value. The detailed results of the above Phase 2 clinical study will be published in a peer-reviewed journal. Conclusion and Future Direction The latest clinical results presented at this year's ADA conference highlight Gan & Lee Pharmaceuticals' leading position in the development of long-acting antidiabetic therapies. Building on these positive outcomes, the company will continue to advance the research and development of innovative treatments for diabetes. Currently, Gan & Lee has initiated and is accelerating large-scale Phase 3 clinical programs in China for bofanglutide injection and GZR4 injections for the treatment of type 2 diabetes, aiming to provide more effective treatment options for patients with diabetes. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin ®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin ®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin ® 30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin ® 30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine ®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine ®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.
